Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib plus Fruquintinib in RAS-mutant Advanced CRC
NCT06985316Not yet recruiting
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of tunlametinib in colorectal cancer (CRC). Primary endpoint: Progress Free Survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
tunlametinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06985316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06985316.